Subscribe to RSS
DOI: 10.1055/s-2002-32963
Metallation and Functionalisation of Dihydrodipyridopyrazines
Publication History
Publication Date:
25 July 2002 (online)
![](https://www.thieme-connect.de/media/synlett/200208/lookinside/thumbnails/10.1055-s-2002-32963-1.jpg)
Abstract
We describe the lithiation of the recently prepared 5,10-dimethyl-5,10-dihydrodipyrido[2,3-b:3,2-e] and [2,3-b:2,3-e]pyrazines 1 (R = CH3) and 2 (R = CH3), respectively. Interestingly while 1 was metallated at the pyridine ring, 2 was lithiated at the methyl groups. Reactions with electrophiles led to new functionalised dihydrodipyridopyrazines.
Key words
dihydrodipyridopyrazines - lithiation - functionalisation
-
1a
Pratt WB.Ruddon RW.Ensminger WD.Maybaum J. The Anticancer Drugs 2nd ed.: Oxford University Press; Oxford: 1994. -
1b
Denny WA. Cancer Chemother. Agents 1995, 218 -
1c
Graham SL.Williams TM. Exp. Op. Ther. Pat. 1996, 6: 1295 -
1d
Singh SB.Lingham RB. Exp. Op. Ther. Pat. 1996, 5: 1589 -
1e
Boger DL.Johnson DS. Angew. Chem., Int. Ed. Engl. 1996, 35: 1438 -
1f
Leonard DM. J. Med. Chem. 1997, 40: 2981 -
1g
Lerner EC.Hamilton AD.Sebti SM. Anti-Cancer Drug. Des. 1997, 12: 229 -
1h
Pierré A.Atassi G.Devissaguet M.Bisagni E. Drugs of the Future 1997, 22: 53 -
1i
Boger DL.Boyce CW.Garbaccio RM.Goldberg JA. Chem. Rev. 1997, 97: 787 -
1j
Takemura Y.Jackman AL. Anti-Cancer Drugs 1997, 8: 3 -
2a
Delfourne E.Darro F.Bontemps-Subielos N.Decaestecker C.Bastide J.Frydman A.Kiss R. J. Med. Chem. 2001, 44: 3275 -
2b
Vicker N.Burgess L.Chuckowree SI.Dodd R.Folkes AJ.Hardick DJ.Hancox TC.Miller W.Milton J.Sohal S.Wang S.Wren SP.Charlton PA.Dangerfield W.Liddle C.Mistry P.Stewart AJ.Denny WA. J. Med. Chem. 2002, 45: 721 -
2c
Gamage SA.Spicer JA.Rewcastle GW.Milton J.Sohal S.Dangerfield W.Mistry P.Vicker N.Charlton PA.Denny WA. J. Med. Chem. 2002, 45: 740 -
2d
Antonini I.Polucci P.Magnano A.Gatto B.Palumbo M.Menta E.Pescalli N.Martelli S. J. Med. Chem. 2002, 45: 696 - 3
Rodriguez I.Kuehm-Caubère C.Vinter-Pasquier K.Renard P.Pfeiffer B.Caubère P. Tetrahedron Lett. 1998, 39: 7283 - 4
Blanchard S.Rodriguez I.Kuehm-Caubere C.Renard P.Pfeiffer B.Guillaumet G.Caubère P. Tetrahedron 2002, 58: 3513 -
5a
Caubère P. Acc. Chem. Res. 1974, 7: 301 -
5b
Caubère P. Top. Curr. Chem. 1978, 73: 50 -
5c
Caubère P. Rev. Heteroat. Chem. 1991, 4: 78 -
5d
Caubère P. Chem. Rev. 1993, 93: 2317 -
5e
Caubère P. J. Chin. Chem. Soc. 1998, 45: 451 ; and references cited in these reviews - 6
Caubère P,Guillaumet G,Rodriguez I,Vinter-Pasquier K,Kuehm-Caubère C,Blanchard S,Atassi G,Pierre A,Pfeiffer B, andRenard P. inventors; Eur. Pat. Appl. EP 96986. ; Chem. Abstr. 2000, 132, 22978 -
7a
Mongin F.Quequiner G. Tetrahedron 2001, 57: 4059 ; and references cited therein -
7b
Turck A.Plé N.Mongin F.Quéguiner G. Tetrahedron 2001, 57: 4489 ; and references cited therein
References
Experimental Procedure: The
following procedure for the synthesis of 5,10-dimethyl-5,10-dihydrodipyrido[2,3-b;3,2-e]pyrazin-4-carbaldehyde 4k is representative. Under inert atmosphere,
to a solution of n-butyllithium (0.59
mL, 0.94 mmol, 1.6 M in hexane) in THF (2 mL), was added, at
-10 °C,
5,10-dimethyl 5,10-dihydrodipyrido[2,3-b;3,2-e] pyrazine 1 (100
mg, 0.47 mmol). After stirring at the same temperature for 1.0 h, N,N-dimethylformamide
(146 µL, 1.88 mmol) was added. The mixture was allowed
to warm at r.t., quenched with water and extracted with CH2Cl2.
The combined extracts were dried over MgSO4, filtered
and concentrated in vacuo. The crude product was purified by column
chromatography on silica gel (eluent EtOAc/hexane: 10/90)
to afford the desired compound 4k. Mp 184-185 °C. IR
(KBr): 1683 cm-1. 1H
NMR (250 MHz, CDCl3): δ = 3.13 (s,
3 H, CH3), 3.37 (s, 3 H, CH3), 6.62 (m, 2
H, H6 and H7), 6.78 (d, 1 H, H3, J = 5.3 Hz),
7.52 (d, 1 H, H2, J = 5.3
Hz), 7.67 (dd, 1 H, H8, J = 4.4,
1.9 Hz), 9.86 (s, 1 H, CHO).
13C
NMR (62.5 MHz, CDCl3): δ = 28.2, 43.9,
116.2, 117.1, 119.9, 124.2, 132.4, 134.4, 138.0, 141.0, 148.2, 151.5, 188.5.
MS: m/z = 241 (M + H)+.
Experimental Procedure : The following procedure for the synthesis of 2-[10-(2-oxo-ethyl)dipyrido[2,3-b;2,3-e]pyrazin-5(10H)-yl] acetaldehyde 6e is representative. Under insert atmosphere, to a solution of n-butyllithium (1.2 mL, 1.88 mmol, 1.6 M in hexane) in THF (2mL) was added, at -10 °C, 5,10-dimethyl-5,10-dihydrodipyrido[2,3-b;2,3-e]pyrazine 2. After stirring at the same temperature for 5 h, N,N-dimethylformamide (146 µL, 1.88 mmol) was added. The mixture was allowed to warm at r.t., quenched with water and extracted with CH2Cl2. The combined extracts were dried over MgSO4, filtered and concentrated in vacuo. The crude solid was washed with pentane and dried to give 6e. Mp 179-180 °C. IR (KBr): 1729 cm-1. 1H NMR (250 MHz, CDCl3): δ = 4.59 (s, 4 H, CH2), 6.48 (dd, 2 H, H3 and H8, J = 7.8, 4.9 Hz), 6.55 (dd, 2 H, H4 and H9, J = 7.8, 1.5 Hz), 7.29 (dd, 2 H, H2 and H7, J = 4.9, 1.5 Hz), 9.62 (s, 2 H, CHO). 13C NMR (62.5 MHz, CDCl3): δ = 51.4, 117.1, 117.8, 130.7, 138.6, 146.2, 198.8. MS: m/z = 315 (M + H + HCOOH)+.
10All new compounds were fully characterised by 1H NMR, 13C NMR, MS and IR spectra.